RxDoctor Payments Data

Joseph Souza, MD

Clinical Cardiac Electrophysiology · Lexington, KYNPI 1336145457

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $76,850 of the $110,186 with a category attached, or 69.7%. 23 manufacturers reported payments, led by Medtronic at 47.1% of the total. Reporting peaked in 2019 at $55,573 and has fallen 98.2% since, to $990 in 2025.

$110,186in general payments, 2019–2025

Across 339 payments — averaging $325.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$52K
  • Johnson & Johnson$50K
  • Abbott$4K
  • Philips North America LLC$1K
  • Altathera Pharmaceuticals LLC$944
  • Atricure, Inc.$463
  • plus $2K from 17 others
$93,858in research payments, 2019–2025

Across 61 payments — averaging $1538.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$90K
  • Abbott$4K

What the payments were for

  • Consulting fees$9,6009%
  • Speaking & faculty fees$76,85070%
  • Travel & lodging$9,4909%
  • Food & beverage$14,23213%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,186 in reported general payments places this provider in the 85th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

See all clinical cardiac electrophysiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$81,263
Medicare patients
646
Services billed
1,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$70,999
XareltoRivaroxaban12$14,279
Flecainide Acetate18$666
Metoprolol Succinate37$577
Amiodarone Hcl39$542
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$226
Doxycycline Hyclate34$152
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$121
Carvedilol17$34
Cephalexin14$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$70,99983 claims
Johnson & JohnsonXarelto$49,828$14,27912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

Other clinical cardiac electrophysiology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →